Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Oncology

Search Medical Condition
Please enter condition
Please choose location from dropdown

Follicular Lymphoma Clinical Trials

A listing of Follicular Lymphoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (418) clinical trials

The purpose of this study is to evaluate the safety and efficacy of two INCB050465 treatment regimens in participants diagnosed with relapsed or refractory marginal zone lymphoma (MZL) who are naive to or were previously treated with a Bruton's tyrosine kinase (BTK) inhibitor.

Phase

This is a multi-center Phase 1/2 open label trial of G100 in patients with low grade NHL. G100 is composed of glucopyranosyl lipid A in a stable emulsion (GLA-SE) and is a potent TLR4 (toll-like receptor-4 agonist. In this study, G100 will be administered by direct injection (intratumorally) into tumors ...

Phase N/A

The purpose of this study is to evaluate the safety and tolerability of INCB050465 when combined with bendamustine and obinutuzumab in relapsed or refractory follicular lymphoma (FL).

Phase

The purpose of this study is to compare INCB050465 with idelalisib for objective response rate (ORR) in subjects with relapsed or refractory follicular lymphoma (FL).

Phase

Primary: To compare the efficacy of SAIT101 with rituximab licensed in the European Union (hereafter designated MabThera®, brand name in EU) when administered as a first-line immunotherapy in patients with low tumor burden follicular lymphoma (LTBFL).

Phase

Durvalumab in Pediatric and Adolescent Patients

This trial will assess the safety and tolerability of Durvalumab in children and adolescents and also study how Durvalumab is processed in their bodies.

Phase

Geriatric Assessment Intervention for Reducing Toxicity in Older Patients With Advanced Cancer

PRIMARY OBJECTIVES: I. To determine if providing information regarding geriatric assessment (GA) and GA-driven recommendations to oncology physicians reduces clinician-rated grade 3-5 toxicity in patients aged 70 and over with advanced cancer starting a new treatment regimen. SECONDARY OBJECTIVES: I. Proportion of patients who are alive at 6 months after ...

Phase N/A

In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies

The purpose of this study is to test the safety of giving the patient special cells from a donor called "Modified T-cells". The goal is to find a safe dose of modified T-cells for patients with relapsed B cell leukemia or lymphoma after a blood SCT. The investigators also want ...

Phase

Anti-CD22 CAR-T Cell Therapy Targeting B Cell Malignancies

Clinical success with chimeric antigen receptor (CAR)- based immunotherapy for leukemia has been accompanied by the associated finding that antigen-escape variants of the disease are responsible for relapse. Despite anti-CD19 CAR-T exhibited the ability to re-induce remissions for many patients with relapsed and refractory B cell malignancies, a part of ...

Phase

Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas Chronic Lymphocytic Leukemia or B-Cell Prolymphocytic Leukemia

PRIMARY OBJECTIVES: I. To assess the safety of adoptive therapy using ex vivo expanded autologous memory T cells (central memory T cells [Tcm] or nave and memory T-cells [Tn/mem]) that are enriched and genetically modified to express a CD19-specific, hinged optimized, CD28-costimulatory chimeric antigen receptor (CAR) as well as a ...

Phase